
AMENDMENTS TO THE CLAIMS

The following **Listing of Claims** replaces all prior versions, and listings, of claims in this Application.

LISTING OF CLAIMS

- 1. (currently amended) A pharmaceutical composition in a closed container, said emposition comprising a meiosis activation substance having a low oxygen content, and in a container wherein the oxygen content in the container is less than about 0.01 moles oxygen per liter said and the closed container is capable of maintaining the low oxygen content of oxygen.
 - 2. (cancelled)
- 3. (currently amended) The pharmaceutical composition of in a closed container according to claim 1, wherein the low oxygen content is below less than about 0.001 moles of oxygen per liter of the volume of the container.
- 4. (currently amended) The pharmaceutical composition in a closed container according to of claim 1, wherein the low oxygen content is below less than about 0.0001 moles of oxygen per liter of the volume of the container.
- 5. (currently amended) A pharmaceutical composition in a closed container comprising (i) a container and (B) a composition comprising (i) a solid composition of a meiosis activation substance, (ii) an additive, and (iii) an atmosphere with an a low oxygen content of less than 10% contained therein, and wherein the closed container is capable of maintaining the low oxygen content of oxygen.
 - 6. (currently amended) The pharmaceutical composition in a closed-container





according to of claim 5, wherein the solid composition of a meiosis activation substance has a high aqueous solubility.

Ţ

7. (cancelled)


- 8. (currently amended) The pharmaceutical composition of in a closed container according to claim 5, wherein the oxygen content of the atmosphere is less than below 5%.
- 9. (currently amended) The pharmaceutical composition of in a closed container according to claim 5 8, wherein the oxygen content of the atmosphere is less than below 1%.
- 10. (currently amended) The pharmaceutical composition of in a closed container according to claim 5, wherein the atmosphere contains more than over 90% nitrogen or argon.
- 11. (currently amended) The pharmaceutical composition of in a closed container according to claim 10.5, wherein the atmosphere contains more than over 99% nitrogen or argon.
- 12. (currently amended) The pharmaceutical composition of in a closed container according to claim 5, wherein the solid composition has a water content below of less than about 10%.
- 13. (currently amended) The pharmaceutical composition of in a closed container according to claim 5 12, wherein the solid composition has a water content of less than below about 5%.
- 14. (currently amended) The pharmaceutical composition of in a closed container according to claim 5 13, wherein the solid composition has a water content below of less than



about 1%.

- 15. (currently amended) The pharmaceutical composition in a closed container according to of claim 5, wherein the solid composition has an organic solvent content of less than below about 10%.
- 16. (currently amended) The pharmaceutical composition in a closed container according to claim 5 15, wherein the solid composition has an organic solvent content below of less than about 5%.
- 17. (currently amended) The pharmaceutical composition in a closed container according to of claim 5 16, wherein the solid composition has an organic solvent content of less than below about 1%.
- 18. (currently amended) The pharmaceutical composition in a closed container according to of claim 5, wherein the meiosis activation substance content is makes up less than below about 10% of the composition contained in the container by weight.
- 19. (currently amended) The pharmaceutical composition in a closed container according to of claim 5 18, wherein the meiosis activation substance content is makes up less than below about 2% of the composition contained in the container by weight.
- 20. (currently amended) The pharmaceutical composition in a closed container according to of claim 5 19, wherein the meiosis activation substance content is makes up less than below about 1% of the composition contained in the container by weight.
 - 21. (currently amended) The pharmaceutical composition in a closed-container





according to of claim 1, wherein the meiosis activation substance is a compound exhibiting a percentage germinal vesicle breakdown which is 50% higher than a control.

- 22. (currently amended) The pharmaceutical compositions in a closed container according to composition of claim 1, wherein the meiosis activation substance is selected from 4,4-dimethyl-5 α -cholesta-8,14,24-triene-3 β -ol; 4,4-dimethyl-5 α -cholest-8,14,24-trien-3 β -ol hemisuccinate; 5 α -cholest-8,14-dien-3 β -ol; 5 α -cholest-8,14-dien-3 β -ol hemisuccinate; (20S)-cholest-5-en-3 β ,20-diol; 3 β -hydroxy-4,4-dimethyl-5 α -chola-8,14-dien-24-oic acid-N-(methionine) amide; cholest-5-en-16 β -ol; and or (20S)-20-[(piperidin-1-yl)methyl]-4,4-dimethyl-5 α -pregna-8,14-dien-3 β -ol.
- 23. (currently amended) The pharmaceutical composition in a closed contained according to of claim 5, wherein the additive is a protein or a phosphorglyceride phosphoglyceride.
- 24. (currently amended) The pharmaceutical composition in a closed container according to of claim 23, wherein the additive protein is serum albumin.
- 25. (currently amended) The pharmaceutical composition in a closed container according to of claim 24, wherein the serum albumin is human serum albumin or recombinant form human serum albumin.
- 26. (currently amended) The pharmaceutical composition in a closed container according to of claim 5, wherein the additive content is above makes up at least about 90% of the content of the composition contained in the container.
 - 27. (currently amended) The pharmaceutical composition of in a closed container

according to claim 5 26, wherein the additive content is above makes up at least about 98% of the composition contained in the container.

- 28. (currently amended) The pharmaceutical composition in a closed container according to of claim 5 27, wherein the additive content is above makes up at least about 99% of the composition contained in the container.
- 29. (currently amended) The pharmaceutical composition in a closed container according to of claim 5, said wherein the container having comprises one or more hollow spaces and wherein at least one of the hollow spaces contains a composition comprising (i) the a solid composition of a meiosis activation substance with a high aqueous solubility, (ii) the additive, and (iii) the atmosphere with a low oxygen content.
- 30. (currently amended) The pharmaceutical composition in a closed container according to of claim 5, wherein an aqueous media is added to the solid composition to form an aqueous solution.
- 31. (currently amended) The pharmaceutical composition in a closed container according to of claim 30, wherein the meiosis activation substance in the aqueous solution is in a concentration above of at least about 100 µg/ml.
- 32. (currently amended) The pharmaceutical composition in a closed container according to of claim 30, wherein the meiosis activation substance in the aqueous solution is in a concentration above of at least about 10 μg/ml.
- 33. (currently amended) The pharmaceutical composition in a closed container according to of claim 30, wherein the meiosis activation substance in the aqueous solution is in a



concentration above of at least about 1 µg/ml.

- 34. (currently amended) The pharmaceutical composition in a closed container according to of claim 30, wherein the meiosis activation substance in the aqueous solution is in a concentration above of at least about 0.001 μg/ml.
- 35. (currently amended) The pharmaceutical composition in a closed container according to of claim 30, wherein the aqueous media has an organic solvent content of less than about 0.1%.
- 36. (currently amended) The pharmaceutical composition in a closed container according to of claim 30 35, wherein the aqueous media has an organic solvent content of less than about 0.05%.
- 37. (original) A process for preparing a pharmaceutical composition in a closed container, comprising:
- a) preparing a solid composition comprising a meiosis activation substance and an additive;
 - b) adding the solid composition to the container;
 - c) freeze drying the composition; and
 - d) closing the container in vacuo.
- 38. (currently amended) The process of according to claim 37, wherein the preparation of the solid composition is performed *in vacuo*.
- 39. (currently amended) The process according to claim 37, wherein the preparation of the solid composition is <u>performed</u> in an atmosphere having <u>a low content of an oxygen</u>

content of less than about 0.01 moles per liter.

- 40. (currently amended) A process for preparing a pharmaceutical composition in a closed container, said process comprising:
- a) preparing a solid composition comprising a meiosis activation substance and an additive;
 - b) filling the solid composition into the container;
- c) filling the container with an atmosphere having a low content of having an oxygen content of less than 10%; and
 - d) closing the container.
- 41. (currently amended) The process of according to claim 40, wherein the solid composition is prepared in an atmosphere having a low content of an oxygen content of less than about 0.01 moles per liter.
- 42. (currently amended) A process for increasing the stability of a pharmaceutical composition in a closed container comprising:
- a) preparing a solid composition comprising a meiosis activation substance having <u>an</u> a <u>low content of oxygen content of less than about 0.01 moles per liter and an additive;</u>
 - b) filling the solid composition into the container;
- c) filling the container with an atmosphere having <u>an a low content of oxygen content of less than 10%</u>; and
 - d) closing the container.

